[HTML][HTML] Pan-cancer characterization of metabolism-related biomarkers identifies potential therapeutic targets
G Bi, Y Bian, J Liang, J Yin, R Li, M Zhao… - Journal of translational …, 2021 - Springer
Background Generally, cancer cells undergo metabolic reprogramming to adapt to energetic
and biosynthetic requirements that support their uncontrolled proliferation. However, the …
and biosynthetic requirements that support their uncontrolled proliferation. However, the …
Genetic alterations associated with multiple primary malignancies
J Nyqvist, A Kovács, Z Einbeigi, P Karlsson… - Cancer …, 2021 - Wiley Online Library
Breast cancer (BC) patients are frequently at risk of developing other malignancies following
treatment. Although studies have been conducted to elucidate the etiology of multiple …
treatment. Although studies have been conducted to elucidate the etiology of multiple …
[HTML][HTML] Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 …
N Li, M Zethoven, S McInerny, L Devereux… - NPJ breast …, 2021 - nature.com
Bi-allelic loss-of-function (LoF) variants in the base excision repair (BER) gene NTHL1
cause a high-risk hereditary multi-tumor syndrome that includes breast cancer, but the …
cause a high-risk hereditary multi-tumor syndrome that includes breast cancer, but the …
[HTML][HTML] Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
MM Bjaanæs, G Nilsen, AR Halvorsen, HG Russnes… - BMC cancer, 2021 - Springer
Background Genetic alterations are common in non-small cell lung cancer (NSCLC), and
DNA mutations and translocations are targets for therapy. Copy number aberrations occur …
DNA mutations and translocations are targets for therapy. Copy number aberrations occur …
[PDF][PDF] Methylated PLK2 is a prognostic biomarker in taxane-treated breast cancers
P Chivers, L Lattanzio, O Garrone, D Vivenza, N Syed… - academia.edu
Background: In search of potential biomarkers of drug responsiveness the tumour
suppressor PLK2 has been identified as a mediator of taxane sensitivity in some tumour …
suppressor PLK2 has been identified as a mediator of taxane sensitivity in some tumour …